Novo Nordisk To Slash GLP-1 Drug Prices By Up To 50% In US Starting 2027 - Eli Lilly (NYSE:LLY), Novo Nordisk (NYSE:NVO)

Group 1 - Novo Nordisk plans to cut the list prices of its GLP-1 drugs by up to 50% in the U.S. starting in 2027, with new prices set at $675 per month, down from current prices ranging from $1,027 to $1,350 per month [1] - The price reduction will impact the obesity injection Wegovy, the diabetes shot Ozempic, and the oral diabetes drug Rybelsus [1] Group 2 - Out-of-pocket costs for commercially insured patients using Novo's drugs vary significantly, with some patients paying as little as $25 per month under optimal coverage, while those in high-deductible plans may pay nearly the full list price until meeting their deductible [2] - The enrollment in high-deductible plans has been increasing in recent years due to lower premium trade-offs, leading some patients to delay or forgo treatment [2] Group 3 - Novo Nordisk is ranked in the 75th percentile for quality and the 47th percentile for value according to Benzinga's Edge Rankings, indicating mixed performance [3] - Year-to-date, Novo Nordisk stock has declined by 26.34%, and on the latest trading day, it dropped 2.62% to close at $38.59 [3]